Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink
Exelixis (NASDAQ:EXEL) executives and investors spent part of the discussion at a Leerink event focusing on recent renal cell carcinoma (RCC) data, evolving treatment sequencing debates, and the...